echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > FXR agonist ASC42 treatment NASH: FDA approved IND.

    FXR agonist ASC42 treatment NASH: FDA approved IND.

    • Last Update: 2020-10-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Pharmaceutical company Gannex Pharma announced today that its candidate drug ASC42 for the treatment of non-alcoholic fatty liver (NASH) research new drug application (IND) has been approved by the FDA.
    ASC42 is a new nonsteroidal selective strong-acting nicol X-subject (FXR) agitant.
    in two NASH animal models, ASC42 significantly improved liver fat degeneration, inflammation and fibrosis.
    Gannex Pharma has two other drug candidates, ASC40 and ASC41, in the clinical phase of its NASH pipeline.
    in Phase II clinical trials (FASCINATE-1 studies), oral fatty acid lysase (FASN) inhibitor ASC40 (TVB-2640) has been shown to significantly reduce liver fat levels at a 61% response rate in the 50 mg group.
    ASC41 is a liver-targeted pre-drug whose active part (ASC41-A) is β TRS-A.
    it is expected that the ASC42 can be used alone or in federation with the ASC40 or ASC41.
    Handan He, chief scientific officer of Gannex Pharma, said: "We are pleased that the FDA has approved THED for ASC42 for NASH.
    NASH is an increasingly prevalent disease and there is currently no approved treatment.
    this is an important milestone that allows us to begin clinical trials this year to meet the medical needs of the treatment NASH."
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.